<SEC-DOCUMENT>0001104659-25-033738.txt : 20250410
<SEC-HEADER>0001104659-25-033738.hdr.sgml : 20250410
<ACCEPTANCE-DATETIME>20250410160149
ACCESSION NUMBER:		0001104659-25-033738
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250410
FILED AS OF DATE:		20250410
DATE AS OF CHANGE:		20250410

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		25828291

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2511968d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN PRIVATE
ISSUER</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>PURSUANT TO RULE 13a-16
OR 15d-16 OF THE </B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: -6.85pt"><B>SECURITIES EXCHANGE ACT
OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of April 2025</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-39446</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact Name of Registrant as Specified in Its
Charter</I>)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive office)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="width: 14%"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 10, 2025, CureVac N.V. (the &ldquo;Company&rdquo;) issued
a press release announcing the Company&rsquo;s financial results for the fourth quarter and full-year 2024 and provided business updates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 50%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 3%; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 47%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/&nbsp;Alexander Zehnder</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: April 10, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86px; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="width: 10px; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-top: 5pt; text-align: center"><A HREF="tm2511968d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 5pt"><A HREF="tm2511968d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated April 10, 2025</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2511968d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CureVac Announces Financial Results for the
Fourth Quarter and Full-Year 2024<BR>
and Provides Business Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: Red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Strategic Milestone Achievement and Increased Financial Discipline
Underscore Year of Corporate Transformation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Completed enrollment</B> of Part&nbsp;B of Phase 1 glioblastoma study with investigational precision
immunotherapy CVGBM; <B>Part&nbsp;B first data readout anticipated in H2 2025</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Filed
                                            IND and CTA submissions</B> for Phase 1 study with proprietary off-the-shelf program in squamous
                                            non-small cell lung cancer (sqNSCLC)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Received
                                            FDA clearance</B> to proceed with sqNSCLC Phase 1 study; <B>expected to start in H2 2025</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Invoiced
                                            &euro;10 million milestone payment</B> following initiation of Phase 1 of the combined Phase
                                            1/2 study of a seasonal influenza/COVID-19 combination vaccine; program fully licensed to
                                            GSK</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Received
                                            positive validity decision</B> for patent EP 3 708 668 B1 in amended form from European Patent
                                            Office (EPO) in inter partes proceedings against BioNTech SE</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Jury
                                            trial in U.S. litigation</B> postponed to September&nbsp;8, 2025, by the District Court of
                                            the Eastern District of Virginia</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>Cash
                                            and cash equivalents position of &euro;481.7 million</B> as of December&nbsp;31, 2024; <B>reaffirming
                                            expected cash runway into 2028</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt"><B>CureVac <FONT STYLE="font-family: Times New Roman, Times, Serif">to host conference call and
                                                                                                                                webcast</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> today at 9 a.m.&nbsp;EST / 3 p.m.&nbsp;CET; details
                                                                                                                                below and under </FONT>https://www.curevac.com/en/newsroom/events/</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>T&Uuml;BINGEN,
Germany/</B></FONT><B>BOSTON, USA</B> &ndash; <B>April&nbsp;10, 2025 </B>&ndash; CureVac N.V. (Nasdaq: CVAC) (&ldquo;CureVac&rdquo;),
a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;),
today announced financial results for the fourth quarter and full-year 2024 and provided a business update.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commenting on the quarter Dr.&nbsp;Alexander Zehnder,
Chief Executive Officer of CureVac said:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&ldquo;The fourth quarter of 2024
marked a strong finish to a year of significant transformation for CureVac. We strategically repositioned the company around impactful
R&amp;D and technology innovation, which enabled us to advance several novel development programs, leveraging our unique mRNA platform.
The successful restructuring and improved financial discipline position the company for stronger performance, supported by recent validation
of our intellectual property in Europe.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Selected Business Updates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Protection of Intellectual Property Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Litigation in Europe was successfully advanced
with a positive ruling by the Opposition Division of the European Patent Office (EPO), announced on March&nbsp;27, 2025, confirming the
validity of CureVac&rsquo;s European patent EP 3 708 668 B1, subject to amendments to specify the scope of protection. The decision is
appealable. The patent describes a foundational invention of CureVac, called split poly-A tail technology, which aims to enhance medical
efficacy by improving expression of the protein encoded on an mRNA construct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In its decision, the Opposition Division largely
dismissed the opposition originally filed by BioNTech SE in April&nbsp;2023 challenging the patent&rsquo;s validity and maintained the
patent in amended form. The ruling represents a major milestone in the ongoing patent dispute between CureVac and BioNTech in Germany,
which involves a total of six intellectual property rights. CureVac believes that this patent is infringed in its amended form. An infringement
hearing is scheduled for July&nbsp;1, 2025, before the Regional Court D&uuml;sseldorf. A positive infringement decision would trigger
proceedings to assess damages in the same court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&ldquo;The positive litigation
development in Europe sends a strong message that reinforces the strength and impact of our patent portfolio, which is one of the broadest
and most diverse portfolios in the entire mRNA space,&rdquo; said Dr.&nbsp;Zehnder. &ldquo;Our breakthrough and pioneering inventions
have contributed significantly to innovation in mRNA medicine and most assuredly deserve formal recognition where due.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The next milestone
in the European litigation will be a hearing to rule&nbsp;on the validity of European patent </FONT>EP 4 023 755 B1 scheduled for May&nbsp;13-15,
2025, before the same EPO board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Oncology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac aims to create breakthrough treatment
options for earlier settings of multiple solid tumor types and is strengthening its clinical development pipeline with two complementary
approaches: off-the-shelf precision immunotherapies targeting tumor antigens shared across different patient populations and/or tumor
types and fully personalized precision immunotherapies based on a patient&rsquo;s individual tumor genomic profile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>New off-the-shelf program in squamous non-small
cell lung cancer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac&rsquo;s new program for a shared-antigen
precision immunotherapy targeting squamous non-small cell lung cancer (sqNSCLC) is on track with recent Investigational New Drug (IND)
and Clinical Trial Application (CTA) submissions to regulatory authorities in the U.S. and Europe, respectively. With the FDA clearance
received, as reported on April&nbsp;7, 2025, to proceed with the Phase 1 study of CureVac&rsquo;s investigational precision immunotherapy,
CVHNLC, in patients with sqNSCLC, dosing of the first patient is expected in the second half of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CVHNLC is a multiepitope mRNA-based precision
immunotherapy consisting of two different mRNA constructs encoding a total of eight tumor-associated antigens with prevalence across sqNSCLC
patients. Four of the encoded antigens represent established antigens, while the other four are novel antigens lying outside of the exome
space identified under the CureVac myNEO Therapeutics collaboration, applying myNEO Therapeutic&rsquo;s advanced AI-powered technology
platform. These novel antigens have not been previously tested in cancer immunotherapy trials. CVHNLC will be tested in combination with
the check point inhibitor pembrolizumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Phase 1, dose-finding, open-label study will
assess the safety and tolerability of CVHNLC as a first line treatment for metastatic disease. In Part&nbsp;A, patients with metastatic
Stage IV sqNSCLC, who have received at least three cycles of pembrolizumab, either as monotherapy or in combination with chemotherapy,
will be enrolled. CVHNLC doses between 100 &micro;g and 400&nbsp;&micro;g will be administered in escalating fashion in combination with
pembrolizumab maintenance therapy for up to 12 months or until disease progression or undue toxicity occurs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&ldquo;Our approach to precision
immunotherapy aims to induce a potent immune response that translates into clinical benefit for patients by applying the ability of mRNA
to precisely and safely guide the immune system to one or more tumor antigens,&rdquo; said Dr.&nbsp;Myriam Mendila, Chief Scientific Officer
at CureVac. &ldquo;With this approach, we aim to target earlier stages of cancer in patients, who have not previously undergone multiple
lines of treatment, where there is a higher chance to increase cure rates.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further discovery work in CureVac&rsquo;s oncology
therapeutic area aims to deliver additional off-the-shelf precision immunotherapies, with the selection of a second clinical candidate
anticipated in 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In parallel, the program for fully personalized
precision immunotherapies is on track with the Phase 1 study expected to begin in the second half of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical off-the-shelf program in glioblastoma</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Part&nbsp;B of CureVac&rsquo;s
Phase 1 study with shared antigen precision immunotherapy candidate CVGBM is ongoing in patients with resected glioblastoma. Part&nbsp;B
successfully completed patient enrollment, adding 20 patients to be treated with CVGBM monotherapy at the recommended dose of 100 &micro;g.
Data from Part&nbsp;B and a decision on advancing the program to Phase 2 are expected in the second half of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac presented preliminary clinical data from
Part&nbsp;A of the CVGBM Phase 1 study in September&nbsp;2024 at the European Society for Medical Oncology (ESMO) Congress and in November&nbsp;at
the Society for Immunotherapy of Cancer (SITC) and the Society for Neuro-Oncology (SNO) congresses. Preliminary immunogenicity results
demonstrated cancer antigen-specific T-cell responses in 77 % of 13 evaluable patients; 84 % of immune responses were being generated
<I>de novo</I>. At the 100 &micro;g dose, the majority of responses were sustainable over a 99-day monitoring period. Induction of cellular
responses was accompanied by systemic cytokine and chemokine activation, indicating innate immune response activation. The treatment was
generally well tolerated, with no dose-limiting toxicities. 91 % of treatment-related adverse events (TRAEs) were mild to moderate systemic
reactions, resolving within 1-2 days post-injection. Seven patients reported nine severe TRAEs, including four serious adverse events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">More
information</FONT> can be found at clinicaltrials.gov (NCT05938387).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prophylactic Vaccines</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Urinary Tract Infections Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November&nbsp;2024, CureVac announced the initiation
of a new program to address urinary tract infections (UTIs), supported by promising preclinical data. UTIs are among the most frequent
bacterial infections, most commonly caused by uropathogenic Escherichia coli (UPEC) bacteria. UPEC can enter the urinary tract, invade
and colonize bladder and kidney tissues. These infections can lead to complications such as kidney damage and urosepsis. UTIs&nbsp;lead
to approximately 8-10 million doctor office visits and 1-3 million emergency department visits per year in the U.S. alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The program is progressing, and it is expected
to file an IND submission in the second half of 2025 for a Phase 1 study to commence in the first half of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Seasonal Influenza/COVID-19 Combination
Vaccine &ndash; Program Licensed to GSK</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November&nbsp;2024, GSK initiated the Phase
1 of a combined Phase 1/2 study to assess reactogenicity, safety and immune responses of a multivalent seasonal influenza/COVID-19 combination
vaccine candidate. The start of the Phase 1 was accompanied by a &euro;10 million milestone payment to CureVac, which was invoiced in
the fourth quarter of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">More
information can be found at clinicaltrials.gov (</FONT>NCT06680375 ).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
previously announced in July&nbsp;2024, CureVac and GSK restructured their collaboration into a new licensing agreement. Under the new
agreement, GSK has assumed full control of the development, manufacturing and global commercialization of mRNA vaccine candidates against
influenza and COVID-19, including combinations. </FONT>All vaccine candidates currently in clinical development are based on CureVac&rsquo;s
proprietary second-generation mRNA backbone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial
Update</B></FONT><B> for the Fourth Quarter and Full-Year 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commenting
on the financial results, </FONT>Axel Sven Malkomes, CureVac&rsquo;s Chief Financial Officer, said:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&ldquo;Our decisive actions in 2024
to enhance fiscal discipline have significantly strengthened our financial foundation, securing a robust cash position that supports our
runway into 2028. This financial strength provides CureVac with the flexibility and resources needed to accelerate innovation in our mRNA
pipeline.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash Position</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
and cash equivalents amounted to &euro;481.7 million at the end of December&nbsp;2024, increasing from &euro;402.5 million at the end
of 2023. The company received the &euro;400 million upfront payment from the new GSK licensing agreement in August&nbsp;2024. In 2024,
cash used in operations was mainly allocated to extraordinary payments amounting to a total of &euro;137 million, related to the termination
of raw material commitments for the first-generation COVID-19 vaccine, CVnCoV, the payment of contract manufacturing organization (CMO)-related
arbitration awards, payments related to the restructuring of the organization and related to the </FONT>litigation to enforce intellectual
property rights. All CMO-related arbitrations are closed, with the last payment made in the third quarter of 2024. Looking forward, there
will be no further payments related to CVnCoV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remaining cash spend was mainly related to
ongoing R&amp;D activities. The company reaffirms its expected cash runway into 2028.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues amounted to &euro;14.5 million and &euro;535.2
million for the three and twelve months ended December&nbsp;31, 2024, respectively, representing a decrease of &euro;8.1 million and an
increase of &euro;481.4 million from &euro;22.6&nbsp;million and &euro;53.8 million for the same periods in 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The increase year-on-year was primarily driven
by the new license agreement with GSK, which closed in July&nbsp;2024. CureVac received a non-refundable upfront payment of &euro;400&nbsp;million.
Under the new license agreement, CureVac has no obligation to perform R&amp;D work in connection with the newly granted licenses, and
GSK is provided with the exclusive right to use CureVac&rsquo;s intellectual property relating to licensed vaccine programs. As such,
the upfront payment was fully recognized in the third quarter of 2024 as revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CureVac and GSK agreed in the new license agreement
that all unfulfilled performance obligations from prior collaborations relating to R&amp;D services had expired. As a result, the remaining
 &euro;80.4 million of contract liabilities for prior collaborations were recognized as non-cash revenue in the third quarter of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&euro;480.4 million of the revenue recognized
in 2024 must therefore be seen as a positive one-time event that will not be repeated in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, in 2024, Curevac reached development
milestones of &euro;15.0&nbsp;million under the previous GSK collaboration for the Phase 1 and Phase 2 transition of the pre-pandemic
avian influenza (H5N1) program, and a development milestone of &euro;10.0 million under the new license agreement for the initiation of
Phase 1 of the combined Phase 1/2 study of a seasonal influenza/COVID-19 combination vaccine. These milestones were recognized as revenue
in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The remaining revenues mainly relate to the CRISPR
collaboration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Operating</I></B></FONT><B><I>
Result</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating loss amounted to &euro;43.8 million
for the three months ended December&nbsp;31, 2024, and operating profit amounted to &euro;177.7 million for the twelve months ended December&nbsp;31,
2024, respectively, representing a decrease of &euro;44.2&nbsp;million and &euro;451.9&nbsp;million from an operating loss of &euro;88.0
million and &euro;274.2 million for the same periods in 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The operating result was affected by several key
drivers partially related to the new strategy and the closing of the first-generation vaccine effort in COVID-19:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Cost
                                            of sales decreased year-on-year mainly due to the change in strategy associated with the
                                            new license agreement with GSK, resulting in adapted R&amp;D activities. As CureVac&rsquo;s
                                            manufacturing organization is no longer supporting revenue generating activities, such costs
                                            are subsequent to the change no longer classified as cost of sales. In addition, higher material
                                            costs appeared in the prior year, which were driven by write-offs of raw materials originally
                                            purchased for the stock piling of the terminated Pandemic Preparedness Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Research
                                            and development expenses increased primarily due to the costs of CureVac&rsquo;s manufacturing
                                            organization classified as R&amp;D expenses rather than cost of sales following the change
                                            in strategy, and due to increased activity in oncology R&amp;D projects. Additionally, 2024
                                            was impacted by extraordinary expenses related to the litigation to enforce intellectual
                                            property rights, and by higher personnel expenses related to the restructuring of the organization.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>General
                                            and administrative expenses decreased compared to the prior year period, mainly driven by
                                            lower personnel expenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Other
                                            operating expenses increased year-on-year due to a partial impairment of CureVac&rsquo;s
                                            production facility.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">While the production facility was initially planned and set
up for commercial (large scale) production, CureVac no longer has large scale production obligations in addition to the strategic re-focus
on technology innovation, research and development. Most parts of the production process can be scaled down to provide products for clinical
production. One production line, which cannot be scaled down, will not be developed further and was impaired with an amount of &euro;32.1
million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>Financial Result (Finance Income and Expenses)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net financial result for the three and twelve
months ended December&nbsp;31, 2024, amounted to &euro;5.2&nbsp;million and &euro;13.2 million, or an increase of &euro;3.7 million and
a decrease of &euro;1.0 million, from &euro;1.5 million and &euro;14.2&nbsp;million, respectively, for the same periods in 2023. This
decrease was mainly driven by lower interest income on cash investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pre-Tax Results</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pre-tax loss was &euro;38.6 million for the three
months ended December&nbsp;31, 2024, and pre-tax profit was &euro;190.9 million for the twelve months ended December&nbsp;31, 2024, compared
to a pre-tax loss of &euro;86.5 million and &euro;260.0 million in the same periods of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Conference call and
webcast details</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">CureVac
will host a conference call and webcast today at 3 p.m.&nbsp;CET / 9 a.m.&nbsp;EST.<BR>
</FONT>Dial-in numbers to participate in the conference call:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Toll-Free:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">+1-877-407-0989</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">+1-201-389-0921</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany:</FONT>&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">0800-182-0040
(landline access) / 0800-184-4713 (cell phone access)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The live webcast link
can be accessed via the newsroom section of the CureVac website at https://www.curevac.com/en/newsroom/events/</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Corresponding
presentation slides will be posted shortly before the start of the webcast.</FONT>A replay will be made available at this website after the event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">CureVac
(Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance</FONT> the field of messenger RNA (mRNA) technology
for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule
for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines
against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac
is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized
precision immunotherapy candidates to treat cancer. It also develops programs in prophylactic vaccines and in treatments that enable
the human body to produce its own therapeutic proteins. Headquartered in T&uuml;bingen, Germany, CureVac also operates sites in the Netherlands,
Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CureVac Media and Investor Relations Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Dr.&nbsp;Sarah Fakih,
Vice President Corporate Communications and Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">CureVac, T&uuml;bingen,
Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">T: +49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">sarah.fakih@curevac.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements of CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that
constitute &ldquo;forward looking statements&rdquo; as that term is defined in the United States Private Securities Litigation
Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss
AG, CureVac Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the &ldquo;company&rdquo;) regarding future
events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the potential
efficacy of the company&rsquo;s vaccine and treatment candidates and the company&rsquo;s strategies, financing plans, cash runway
expectations, the timing and impact of restructuring, growth opportunities and market growth. In some cases, you can identify such
forward-looking statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo;
 &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; &ldquo;expect,&rdquo; &ldquo;may,&rdquo;
 &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or
 &ldquo;should,&rdquo; the negative of these terms or similar expressions. Forward-looking statements are based on management&rsquo;s
current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are
not a guarantee of the company&rsquo;s performance, and you should not place undue reliance on such statements. Forward-looking
statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic
conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct
current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on
third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, ability to
implement our pipeline strategy, possible changes in current and proposed legislation, regulations and governmental policies,
pressures from increasing competition and consolidation in the company&rsquo;s industry, the effects of the COVID-19 pandemic on the
company&rsquo;s business and results of operations, ability to manage growth, ability to implement, maintain and improve effective
internal controls, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety,
fluctuations of operating results due to the effect of exchange rates, delays in litigation proceedings, different judicial outcomes
and other important factors discussed under the caption &ldquo;Risk Factors&rdquo; in the company&rsquo;s annual report on
Form&nbsp;20-F filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on April&nbsp;25, 2024, as such
factors may be updated from time to time in its other filings with the SEC. Such risks and uncertainties may cause the statements to
be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the
company&rsquo;s control and could cause its actual results to differ materially from those it thought would occur. The
forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and
specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such
statements to reflect future events or developments, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For further information, please reference the
company&rsquo;s reports and documents filed with the SEC. You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2511968d1ex99-1img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cash and Condensed Consolidated Profit and Loss
Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(in &euro; millions)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;31,
    2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;31,
    2024</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-size: 10pt">Cash and Cash
    Equivalents</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">402.5</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; width: 17%; text-align: right"><FONT STYLE="font-size: 10pt">481.7</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Three months ended December&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">(in &euro; millions)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">Revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">22.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">14.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cost of Sales, R&amp;D, SG&amp;A, Other Operating Expenses&nbsp;&amp; Other Operating Income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-110.6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-58.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Result</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-88.0</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-43.8</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Financial Result</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Pre-Tax Result</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-86.5</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-38.6</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Twelve months ended December&nbsp;31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">(in &euro; millions)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">Revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">53.8</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">535.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cost of Sales, R&amp;D, SG&amp;A, Other Operating Expenses&nbsp;&amp; Other Operating Income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-328.0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-357.5</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Result</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-274.2</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right">177.7</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Financial Result</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13.2</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Pre-Tax Result</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">-260.0</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">190.9</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2511968d1ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2511968d1ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( *,# 2(  A$! Q$!_\0
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MH[]B*Y^&FGZ/JWCV+7OB<OAC2_$=U=VV@3ZI&O@:-#J#6VH6*LB6XG"F9)U
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M_%$&!.WS #Y=.3]K33$<"/X+?M47K')$8_9T^(\>W&  ))- CB0/GDR<?+U
MS7!EGA?P[E68QS?)N"N&LGS"$JDZN98##\.T<90E4A*G4Y*N#J0KWK1G*C4=
M.7O4ZE123@VGVYOX]<1<097+(L_\2^+,VR3]S_QC^80XPQ^!Q,,+5IXB@JF"
MGPORU%AZM"EB:2A3M2JT85/L<QZ!^T/^SA\.?VD_"_ACPM\3-)?4=/\ #?C?
MP_XUL&3$-R+W0+AI)M/E8)E]+U[1YM4T+58RZ>;:ZB0-TBP[9/C/^SE\+OV@
M-)\+^&?B=H4^M>'?!WB'3?%>G:'!JVM:9I$VM::B06DUWI^EW-M#J]M:Q/,D
M*7J.MJ99?($/VJX:O.9/VL[IB#:_LU?M77K'[JI\'WLR3QM!;6KG2TCW9X\R
M5,=]O%5Q^T_\2KQV31_V-/VHKPGA7U>#X,>'+1"W";Y-5^,UC/&CX;>PLI#%
MM!:-2RJWWV'AFE-P^K5HT:U%S]E..,HX;V4JEX3<:SKKV3Y93BI+5*346N9W
M_,*V;\"XG$9ABZU#%XFKF\<-3G#"<*\5K%8CZG4A7@H-<-X*4N1TE.5L53O"
M,E^\^!_7]O;B*-8MBJ!#N6,10H5C8(7V1X$@"2-ALJI#,O&\XKQ[Q]\!?AI\
M0?B!\/?BAK^D7I\>?#.34W\'>(-$U?7-%N;:#5VTUM3L=4BT6[LK?5]-U"/3
M8+.[L-7BO+.2PEOX-B1W,RGQI_C7^UM>.5T7]C+[%&PPLWC/]H/X?:*%#_<=
MH_"=IXYG4H 3.A='7*"$W!,AAHW4_P#P4!\4/&+?1?V5/AU9^5,F;W6_BG\3
M-6MC=*GEN8[;3/ ^F74]D8R2)?M,,S.H!A1&%QQT,JQV#JU,3/.:6!G/GC*N
ML^HXGEC54HSC]7C":E"2E*$ERM6=TKI-;YAQ-DN.PD<MI\.\7YGA92H7P-/@
M_/Y.M[&M2K4HIYAC,GPMH5*=.HWB,93IQA%SE&JDZ,\SXG_\$YOV0/C-XVU?
MQ_XS^%3W'BS7I$GUO5-$\9^,O#::E=!=K7%WI'A[Q%!HYO&97N+J]M+.*\O[
MNZN9]1EFE,;+P6F?L%?L*_LX^)?#GQ<&D0?#;4/!.KQ:WI/BWQM\4?%FF^'[
M#4K9)((&DG\6>(;K0IY=MU(8H;I(IV8 VX?$H6U=_L@?M0>.IWC^*G[>_P 3
M;;3[MR]UHOP/\$>$?@V+56)+V6GZ_;W>MZR8B-JK/?65W<1!7,?E/+*9/0/!
M7_!/W]F'PO?6^JZYX$F^+GBJWC"7GC#XV:Q??%7Q%>S,SL]S?/XS6YTN.6<X
M#+IFG::LAAC\WS'CM_+]S^V:N'PKPE;C',L=AI4U">%RV-6564$DN6$JTH4I
M0T47'E<'2YDXV]Q_$U>$J.;YU/,\!X(<-8.OAW&5/B'B+-.#\IS&A4;2C7AE
MG#F59KB:M2,FY3IXW-\-C9.ZH8JCB94Z\/)?$'_!1?P;XOUVZ^'?[+?PQ^)W
M[4/C9+VYTC^V/!ND7.A?"RVU$$K+)K?Q&U&U:SL--@:99&U>***PG$$VW6[4
M)#)+QS_L-_%_]I[QCH'Q%_;S^(&BZMH'AZ[;4_"O[.'PQBNK7P'H'VJ2*]-O
MXI\1SO'=^(6A^Q627+Q>6;EX##'XAGM(H[*3]6/#^@Z3X;L(-)T+1[#0-+LX
MQ;V>EZ/96NFZ39Q*6*QV=A8)#:V2+DX6 $ X##H!M*K!Y-CD ;<LX&<$M]U^
M2^,'G"X_6N!9_2P%X9!E.#H^W4UBLVQ4HUL[IQE"46J-3V<:6'=64O95E0HJ
M?LW.*JJ'+!?4RX#JYXJ4N.LXQG%6%PU2E4H</X+"U,CX>PM2C+FH*KA'B*V;
M9PZ%2-.K2J9]FV;8:-:G#$X?"8>O&E6IY>@Z39:-IUCHFEV-II>DZ3:VEGIV
MG6426UM96MO"L$5O:VL:1I%:1"(PVQ2*W1HXML=NBQB2;H(PP:0D8SMP/IN[
M=N"*@B WC,OF'_Z_OU&?0#UYJ>(J6<!BQ&W<".F=V/P//Y5\\Y595:M2L[SJ
M:W:E?63D[MN[;W;>K[ZGZ)3ITJ=+#4845@Z6&BJ>&PT;)*G"GR1BDM+1@NG8
MFHHHH-PHHHH **** "BBB@"K=*IC+LSHJ*[,\>W?%A2WFQAE8F1=OEH "2)6
M!##BO*M'^)B:S\:/B#\&CX>OK2?P+\+OA)\2I/$\A7^P]6C^+?B_XZ>%8O#]
MD 3YFK>&E^#%UJ&N?.T?E^)M*"@9R?3M1C\Q(QY0E+&2+D3/\LJ$,CPQ*(YX
M),*LL-Y-!9$^6\[DI&!^>'QK_P""??P^^)7B^\^(5MJ%EKOB;Q0FOZ/XY\'_
M +3;_$#]J'X!>._"^NZX=<TKP_KGP1\:_%#0] TVU\(W]Y=6?@:W\$ZOH?AO
MP_'XAUO2;[PKXDBUBTFT0 ^@/@KXV\=ZUXV_:IN/'^H:9#X&\/\ [1MAX*^"
M,L,'V*0^"--^ GP)/BB&\F9V%W.WQSN_B]%$Y&Z.*$)YC(BA.I^-'[1WP(_9
M^;P3'\:OB]\//A7=_$7Q9I?@?P#;>-?%&D:)=^,/%.O:II.@:3HGA^UU*2.X
MU"[EUS7]!BG6SBD%M)=V)N&"SQA_E^X_X)[?"+Q5X?\ $G@[XNZOXC^+?@?7
M=7O_ !-H'POUS2_!.C_"?X)^.]?T>*RU;QG\%O"6@>%++6M U'1KV>^N?AIX
ME\5^,/BAXC^"VI7J3^!M?TR6SOKR'G-/_8;\4:I\1O@1\7?C+\8_#?[0/BCX
M-:;X0LK^]^*OP2TO['JWB/X:>-?BAX@^&?Q>\,>'OA_\1?"_@GP5\6?#'AOX
MMZ[X3USQC/X<\8>'XO%&FZ)\1/!/A#X8KI-]H^K 'T7^U?\ &?XN_!'P%X<U
M[X-_!3P]\:/$GB3XB^$_ LFG^-_C3X=^!/A+PT_CK7X_"OA?5=8\<:QX5^(F
MHS3ZWX_UKPAX6\/:'X=^'_B:_O;W7HBT=N;>&.Z\W^"G[2'QLU[XMV_P*^/W
MP+^&'P\^(%[X9U#Q<$_9Y_:%\1_M-:!X+T.R6&>"/XPZOXI^ '[/.K_"V;Q8
M^I1CX6VS:-K=GXHFTW6X[*>PA\/[;WZ1^+'PMT?XN^#D\(:W>ZE96VG^./AO
MX[MK_39T-Y9^(OA/\3?#'Q:\,2-92_9M-EAA\2^%=(:*&\MKR.[LW@DGMYT^
M8?.W@/\ 8MC^"GCOXG^*?V?_ (U_%#X;^'OC3\6]?^./Q.^&VH1>"OB)X3U+
MXH>+K[37\;>*]"U?XA^$_$?Q&\+WOBZQL;.+4-!B\;7WA"*&V@A\'>'O GFW
MUS?@';?'O]J?PG\$_AQX4^+8L#X^\#WOQ^^'GP*\<>(O"FHV$]K\,IO'WQEL
MO@3J/B[7E,LHO](^&'Q)U73=%\>6<++<:6J:GK4\<7]ARVXG^,_[3OAOX0ZQ
M)X4TOP%\3?C7XVL?#EKX^\7?#[X,:1X?\2^-/ ?PHGO]1T^7XC^)].USQ1X6
MB_L2:^T?Q!!X:\->%G\4?%+XB7VB^+-'^%'@'Q7<>#/$G]C?.$/[!'B%_A%I
MW[/M]\8?">J_"/QOK/@WQO\ M.6LGPEUFW\7?%GXHZ3K/AGQ;\3O%?@+7]-^
M*]GX>^%^F?'7QOX8.O\ C_PW=>$/B1J,>I>*/'DFA^)X=1U>*[T'5\)_\$X?
MAUI7C'XG_$3Q?\</VL/'WC'XS>,M2\?_ !.UJR_:!\:?!UM<O3)-I/@_P_#+
M^SEJ_P +/$T/@KX5^"((/!?PR\ 1:[/X1T;3K:^\0ZAI^N>/]6UKQ!J(!]Z>
M$?%GAWQMX:T/QKX0\2Z3XL\$>*]"TKQ;X7\6:3.EYI&NZ#KUN=8TG7M'UNU:
M32-2TR]TN_TZ33)+=-L\"F5YI(W18\3_ (6I\,O^%AQ_"*7XD>"8_BS+HK>(
MHOAC)XQ\,#XE3>'%DA\_Q#_PA5GJ%OXF71HV:!IM4M;1[$1.GVMTW1*>*_9]
M^ 7PW_9C^'&A_!CX41:YH?PY\+:MKUSX+\,:GK5[KUIX1T[6-8U#63H.@WVI
MQ?VG;>$;:;5M2@T?2M0N-0L='CN8M)T;4($MM,2OS0_9Z_9@\,_M.^ _B[<?
M$'XD?$70?B]\+OVI?^"A'@%_&O@;5_"F@^.?!7Q(\;:_^T'\%O#7QDT#QY+X
M"U3Q]I'C>/\ 9"^-/P[T+P;HDWCSQ#\-/AYH?AWX7:+X6\)K)X!T*]MP#]+-
M-_:G_9NU^S\9ZGX<^/7PD\0VOP\\5V?P_P#';^&_'WAO6V\.^.[^=(K#P=J-
MIH^K7TMKXNUN=9K#1?#\JC7M1OK>:TTVWN9K6ZC3I4^-?PE33_ E]>?$KP7I
M,/Q4_LH?"^/Q!X@T+P]>>-;S6(-/ET72?"UEK6H6$VOZY>+J>F2V7A^U2XU>
MT.I::FHV\-S>6D;_ )W6'_!*+X.IH?P6GU7Q/JVC?$?X+_%JP^,]IXP^&_@W
MPU=:/XR\::#X%L_A+X,O=>^&_P"TL?VG="TR#X8>"].TK1_@K/X4_L/2_@%#
M;Q-\'[CP1X;N-7TV[ZOQ%^S/\-/&/QQ\2?L\^)O'OCZP\(>(_P!GKX$ZQ%X'
MM]6TBXG^)_@?X.^,/B/H.OZ'KWB;6?#E]XNCL/"GC'Q5\-_&NI>(/!.O^!O'
MEUXT\4VVKS>)M535];LH0#U'PY\>?AK^SE\._&/CC]HWXY6U@OBS]H/]H,V.
MH>)-:N]:L]%T+3OC?KOP\\*^']!T;3SK!\/^#_A]X?T[PGH'B>_N1;:#X3UM
M-9O];O\ 3[/5)9D_/GXX?M0?M0^$_C+\5;+X?^*7\0^/_#>D?$@_"_X#:G>V
M6G2>+OB=X=\=?%G2/@C\ K'P9_:&E:[K/A7]H#P1X&^%GB+Q?\9/%>A>*=0\
M#Z?\0_%GC;2_B=X)\'V?AWPAX?\ MGQI^P9!XJ\9^$_$-S\4)-;\+VGQ&U7X
MA>+OA;X^\*:YK'@#QW';_M _$+]H;X>V5]I_@KXE_#M;K6O WC;XFZV^EQ^-
MY?'7@'Q,^A^ _$7B/X8:CXD\!66HG]%-.BEC,ZR2-)'F&2/_ %AC#&%4D^S2
M."TENYB2<M++-</>2WDLDABE@  /%_@;?^._'7P2^#7C7XW?#30O!'QE\6_"
M?X<>(_BQX(6)+Z/P5\2-9\&Z+J'C;P=#>M%KQO(/"OB2XU+0(+L:UJ:W,.GQ
MS)>SHZN2O>BX!(YXHH =1110 4444 %%%% !1110 4444 %%%% !1110!!<0
M+.H5@&(#A<D@+YL;0N^ #N8122*H/!W$$KG<,[2]$T[2;G6;NQT^PLKCQ!J$
M>KZS-9VX@DU+5EL+/2FO[L@GS)CINF:;;!F)?;;?.[D[B44 ;&,_SK@]1^&_
MA#4OB%X<^*UQHEI)\0/"G@[QQX T#Q(P/VW3/"?Q&U?P!K_C#2K<[641:UJW
MPN\"W-R<*P.B0$,<%'** .Y5=I<\88Y&!@@'D@GO\Y=P<\;R  !R^BB@ HHH
$H __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
